Shares of Johnson & Johnson JNJ,
were up 0.9% on trading on Monday as the company approaches the early disclosure of intermediate results from a late-stage clinical trial evaluating its candidate for the single dose of COVID-19 vaccine. J&J said in mid-December that it expects to share the findings of the phase 3 study by the end of January, the third company to test US coronavirus vaccines to announce the results of a phase 3 study. watched closely. The other two vaccines, developed by BioNTech SE BNTX,
/ Pfizer Inc. PFE,
and Modern Inc. MRNA,
both are mRNA-based vaccines that received emergency use authorization from the Food and Drug Administration in December. J&J said in December that it would apply for an emergency authorization for its experimental adenovirus vaccine in February if the results are ready by the end of January. The company is expected to launch its fourth-quarter and full-year earnings on Tuesday. J&J shares have gained 10.9% in the last year, while the S&P 500 SPX,
it is increasing by 15.6%.